Stocktoria
RxSight, Inc. RXST
Nasdaq · XNAS · stock · Ophthalmic Goods · website · IPO 2021-07-30
RxSight, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M |
| R&D expense | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M |
| SG&A expense | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M |
| Interest expense | $19,000 | $21,000 | $3.3M | $4.9M | $3.7M |
| Income tax | $66,000 | $50,000 | $20,000 | $9,000 | $8,000 |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| EPS (diluted) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
| Cash & equivalents | $19.9M | $16.7M | $9.7M | $11.8M | $24.4M |
| Inventory | $31.6M | $22.0M | $17.4M | $14.8M | $8.0M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Shareholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
Source: SEC EDGAR filings · CIK 0001111485 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.